Clinical bottom line
Bempedoic acid is an emerging lipid-lowering agent under investigation for use in patients with chronic kidney disease (CKD) who often exhibit dyslipidemia contributing to heightened cardiovascular risk. Early evidence suggests bempedoic acid may reduce low-density lipoprotein cholesterol (LDL-C) without significant renal adverse effects, offering a potential alternative or adjunct to statins in CKD populations. However, data remain limited regarding long-term cardiovascular and renal outcomes, and its safety and efficacy across CKD stages require further validation before routine clinical adoption.
What the evidence shows
Dyslipidemia in CKD is characterized by elevated triglycerides, altered lipoprotein profiles, and often suboptimal LDL-C control, which contributes to accelerated atherosclerosis and cardiovascular morbidity (Theofilis et al., 2025). Traditional lipid-lowering therapies such as statins have demonstrated benefit but may be limited by side effects or contraindications in advanced CKD.
Bempedoic acid, an adenosine triphosphate-citrate lyase (ACL) inhibitor, acts upstream of HMG-CoA reductase to reduce cholesterol synthesis. It is a prodrug activated primarily in the liver, theoretically minimizing muscle-related adverse effects common with statins. While large-scale CKD-specific trials are pending, emerging clinical data indicate that bempedoic acid effectively lowers LDL-C levels in patients with mild to moderate CKD without significant impact on estimated glomerular filtration rate (eGFR) or electrolyte balance (Theofilis et al., 2025).
Theofilis et al. (2025) review highlights that bempedoic acid may be particularly useful in CKD patients intolerant to statins or requiring additional LDL-C reduction beyond statin therapy. Its renal safety profile appears favorable compared to some other lipid-lowering agents, but the evidence is largely extrapolated from general populations or subgroup analyses.
Caveats and uncertainty
Current evidence on bempedoic acid in CKD is limited by a paucity of randomized controlled trials specifically enrolling patients with advanced CKD or dialysis dependence. Most available data derive from post hoc analyses or studies with small CKD subgroups, limiting generalizability. The impact of bempedoic acid on hard cardiovascular endpoints and CKD progression remains unestablished.
Additionally, the interaction of bempedoic acid with common CKD comorbidities and polypharmacy, including diuretics and immunosuppressants, is not fully characterized (Greenberg et al., 2015; 2020). Potential effects on uric acid metabolism, which may be relevant given the association of hyperuricemia with CKD progression (Arora et al., 2025), warrant further investigation.
Finally, patient adherence and health literacy challenges in CKD populations may influence real-world effectiveness (Dageforde et al., 2013), underscoring the need for comprehensive management strategies beyond pharmacotherapy alone.
How this may change practice
If ongoing and future studies confirm the efficacy and safety of bempedoic acid in CKD patients, it could expand the therapeutic armamentarium for lipid management, especially for those intolerant to or inadequately controlled by statins. Clinicians may consider bempedoic acid as an adjunctive or alternative therapy in selected CKD patients with dyslipidemia, balancing potential benefits against the current evidence gaps.
Routine monitoring of renal function and metabolic parameters would remain essential, with cautious use in advanced CKD until more robust data are available. Integration of bempedoic acid into CKD care pathways should be accompanied by patient education to optimize adherence and address health literacy barriers.